A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Eli Lilly

Protocol Number
I6A-MC-CBBD (GU 115)

To Learn More Call
201-510-0910

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Hoosier

Protocol Number
GU14-182

To Learn More Call
201-510-0910

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-057

To Learn More Call
201-510-0910

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Millennium

Protocol Number
C31005

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers S